Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Macrophage Migration Inhibitory Factor Target Validation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MIF drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MIF Recombinant Protein (Active Homotrimer) High purity (>95%), Endotoxin Controlled (<1 EU/µg). Sequence Verified. Suitable for tautomerase activity assays and receptor binding. |
View MIF Products |
| Gene Delivery | MIF Promise-ORF / Lentivirus Full-length ORF for stable cell lines, enabling high-throughput overexpression screening. |
View MIF Products |
| Benchmark Ab | Anti-MIF Recombinant Antibody (Sequence of Imalumab) Recombinant positive control for blocking assays and ELISA validation. |
View MIF Products |
| Validator | MIF siRNA Set For target knockdown verification and phenotypic assay validation. |
View MIF Products |
| Related Target A | CD74 The primary cognate receptor for MIF; critical for validating MIF-CD74 signaling axis inhibition. |
View CD74 Products |
| Related Target B | CXCR4 G-protein coupled receptor that forms functional complexes with CD74 to mediate MIF-induced leukocyte chemotaxis. |
View CXCR4 Products |
| Related Target C | D-DT (MIF-2) MIF structural homolog (D-dopachrome tautomerase); essential for counter-screening to ensure drug selectivity. |
View D-DT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Trimeric Conformation Stability | HEK293 expressed recombinant MIF preserves the native homotrimeric structure required for biological activity. |
| Tautomerase Enzyme Activity Validation | Sequence-verified, high-purity proteins ensure consistent enzymatic activity in dopachrome methyl ester assays. |
| Selectivity Over Homologs | D-DT (MIF-2) recombinant proteins available for rigorous off-target counter-screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) based on Imalumab sequence included |
| False Positives | Validated siRNA included for target-specific knockdown verification |
Live MIF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MIF therapeutics is intensifying, with major players shifting focus from traditional systemic monoclonal antibodies to small-molecule tautomerase inhibitors and peptide-based antagonists targeting the tumor microenvironment. MIF acts as a pivotal upstream regulator of innate immunity, driving immunosuppression by recruiting myeloid-derived suppressor cells (MDSCs) and polarizing macrophages to an M2-like phenotype. As first-generation systemic therapies reach the clinic, the next wave of R&D is targeting tumor-localized MIF inhibition to overcome resistance to immune checkpoint inhibitors (PD-1/PD-L1).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | OncoMIF, Baxter (Imalumab) | Solid Tumors, Inflammatory Diseases | Blocking Assay (Need high-purity, trimeric MIF antigen to test ligand-receptor inhibition) |
| Small Molecule Inhibitors | Caddis, Novartis (ISO-1 derivatives) | Autoimmune Disorders, Rheumatoid Arthritis | Enzymatic Assay (Need sequence-verified active MIF with functional tautomerase activity) |
| Peptides / Antagonists | Academic spin-offs | Cardiovascular Disease, Sepsis | Epitope Mapping (Need high-purity CD74 and CXCR4 target proteins for competitive binding) |